Clinical Utility Study demonstrates PromarkerD test offers improved treatment options for doctors in the fight against diabetic kidney disease

Well covered by @laoshi regarding the endo update yesterday but interesting media release today regarding PLOS ONE.

 Results published today in the peer-reviewed journal PLOS ONE show the PromarkerD test ranked as more important to physicians than current standard-of-care tests

 78% of doctors were very or extremely likely to use PromarkerD in the future for the management of their diabetes patients

 The Clinical Utility Study shows the PromarkerD predictive test for diabetic kidney disease could significantly change doctors’ treatment decisions and improve outcomes for patients

 The published clinical utility study will form a key element of the dossier supporting a United States PLA code reimbursement application for PromarkerD

MEDIA RELEASE

PLOS ONE Conclusion

PromarkerD could increase adoption of renoprotective interventions in patients at high risk for renal decline and lower the likelihood of aggressive treatment in those at low risk. Further studies are needed to assess patient outcomes with PromarkerD in real-world practice

PLOS ONE